Get the Stockscreener App
2.66
5.34%
-0.15
After Hours:
2.66
Cardiff Oncology Inc stock is traded at $2.66, with a volume of 598.35K.
It is down -5.34% in the last 24 hours and up +30.39% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$2.81
Open:
$2.8
24h Volume:
598.35K
Relative Volume:
0.68
Market Cap:
$179.18M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-2.8602
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
-16.09%
1M Performance:
+30.39%
6M Performance:
-25.91%
1Y Performance:
-37.56%
1-Day Range:
$2.6111
$2.85
1-Week Range:
$2.6111
$3.125
52-Week Range:
$1.90
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.66 | 189.28M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investors Purchase High Volume of Call Options on Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology (FRA:XE7C) EV-to-OCF : -3.04 (As of Dec. 24, 2025) - GuruFocus
Stock Traders Purchase High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - MarketBeat
Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF - MarketBeat
Why analysts raise outlook for Cardiff Oncology Inc. (XE7C) stockTrade Analysis Report & Precise Swing Trade Entry Alerts - Улправда
Short Covering: How analysts revise price targets for ConAgra Brands Inc stockPrice Action & Low Risk Profit Maximizing Plans - moha.gov.vn
Cardiff Oncology Earnings Notes - Trefis
Will Cardiff Oncology Inc. stock benefit from green energy trendsQuarterly Portfolio Summary & Verified Technical Trade Signals - Улправда
Quarterly Earnings: Will SIFYR stock continue dividend increasesMarket Activity Summary & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Cardiff Oncology Inc. stock affected by interest rate hikesWeekly Profit Summary & Weekly Breakout Watchlists - Улправда
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.83 Average Price Target from Analysts - Defense World
Published on: 2025-12-20 05:10:29 - Улправда
Institution Moves: Will Cardiff Oncology Inc. stock benefit from green energy trendsCPI Data & Daily Profit Focused Screening - Улправда
Aug Spikes: Is Cardiff Oncology Inc. stock affected by interest rate hikes2025 Retail Activity & Safe Swing Trade Setup Alerts - Улправда
Can Cardiff Oncology Inc. stock double in next 5 yearsWeekly Trade Review & Accurate Intraday Trading Signals - Улправда
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Aug Big Picture: Can Cardiff Oncology Inc. stock double in next 5 yearsWeekly Trade Summary & Long-Term Safe Investment Ideas - Улправда
Cardiff Oncology (STU:XE7C) EV-to-FCF : -2.30 (As of Dec. 18, 2025) - GuruFocus
Can Cardiff Oncology Inc. stock sustain revenue growthJuly 2025 Momentum & Consistent Return Investment Signals - Улправда
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Hold" by Brokerages - MarketBeat
Operating cash flow per share of Cardiff Oncology, Inc. – LSX:A2P4GU - TradingView — Track All Markets
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Zacks Small Cap Weighs in on CRDF FY2025 Earnings - Defense World
What drives Cardiff Oncology Inc stock priceSmall Cap Stock Opportunities & Free Daily Stock Hotspot Analysis - earlytimes.in
Cardiff Oncology CRDF US - Smartkarma
FY2025 Earnings Forecast for CRDF Issued By Zacks Small Cap - MarketBeat
A new trading data show Cardiff Oncology Inc (CRDF) is showing positive returns. - setenews.com
Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most - Yahoo Finance
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response - Zacks Small Cap Research
Cardiff Presents Phase 1 Data Of Onvensertib In Chronic Myelomonocytic Leukemia At ASH 2025 - Nasdaq
Cardiff oncology reports positive results for onvansertib in leukemia trial - Investing.com
Cardiff oncology reports positive results for onvansertib in leukemia trial By Investing.com - Investing.com India
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 - The Manila Times
Cardiff Oncology Announces Clinical Data from - One News Page
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference - The Manila Times
Is Cardiff Oncology Inc. stock a contrarian buy2025 Key Highlights & Technical Pattern Based Signals - Newser
How Cardiff Oncology Inc. (XE7C) stock stacks up against competitorsMarket Risk Report & Low Volatility Stock Recommendations - Newser
Will Cardiff Oncology Inc. (XE7C) stock announce a stock splitAnalyst Upgrade & Technical Pattern Based Signals - Newser
Can Cardiff Oncology Inc. (XE7C) stock stage a strong rebound this quarter2025 Year in Review & High Accuracy Trade Alerts - Newser
How Cardiff Oncology Inc. (XE7C) stock reacts to stronger dollarJuly 2025 Rallies & Long-Term Investment Growth Plans - Newser
Will Cardiff Oncology Inc. stock outperform Dow Jones indexJuly 2025 Trends & Stepwise Trade Signal Guides - Newser
Cardiff Oncology (CRDF) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Cardiff Oncology Inc. stock a defensive play in 2025CPI Data & Free Daily Entry Point Trade Alerts - Newser
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):